Impact BioMedical Inc. filings document the regulatory record of a biotechnology and health-technology company focused on patented science for biopharmaceuticals, consumer healthcare and wellness. Its disclosures cover operating and financial results, risk factors, going-concern audit language, material events and agreements, and capital-structure matters tied to common stock and convertible preferred stock.
Proxy statements and 8-K reports record shareholder voting matters, board elections, auditor ratification, executive-compensation votes and other governance items. Additional filings address material-event disclosures, security-holder approvals and ownership or conversion activity affecting the company’s equity structure.
Impact BioMedical Inc. (IBO) completed a 1-for-12.62 reverse stock split, effective September 23, 2026. The company said issued and outstanding common shares decreased from approximately 107.8 million to approximately 8.6 million.
The split did not change authorized share counts, par value or common-stock voting rights. No fractional shares were issued; holders otherwise entitled to a fractional share received one full post-split share.
DSS, Inc., identified as a ten percent owner of Impact Biomedical Inc. (IBO), reported direct sales totaling 906 common shares: 723 shares on September 22, 2026, at $0.5500 per share; 27 shares on September 23 at $6.9500; and 156 shares on September 24 at $7.0587. No Rule 10b5-1 plan is reported.
Impact BioMedical Inc. (IBO) reports that Zoar Limited has filed a Registration Statement on Form F-4 in connection with their proposed merger. The Form F-4 includes a preliminary proxy statement/prospectus for the business combination. After effectiveness, a definitive proxy statement/prospectus will be mailed to Impact stockholders for a special meeting to vote on the merger and related matters.
The disclosure emphasizes that these materials will contain important information about Impact, Zoar Limited, Zoar Labs and the proposed merger, and that certain directors and executive officers of each entity may be deemed participants in the proxy solicitation. Standard forward-looking statement cautions and SEC document access details are provided.
IMPACT BIOMEDICAL INC. (symbol: IBO) is the issuer of record for a Form 8-K filing submitted to the SEC.
Impact BioMedical Inc. is implementing a reverse stock split of its common stock at a ratio of 1-for-12.62, effective at 12:01 a.m. Eastern Time on September 23, 2026. This will reduce outstanding shares from approximately 107.8 million to approximately 8.5 million, with fractional shares rounded up to the nearest whole share. The reverse split is being effected in connection with a proposed merger with Zoar Limited and to assist in regaining compliance with NYSE American continued listing requirements, although there is no assurance it will achieve compliance or that the merger will be consummated. Proportional adjustments will apply to outstanding equity awards, related exercise or conversion prices, and shares reserved under equity plans, while the total number of authorized common shares will remain unchanged. After the reverse split, Impact stockholders are expected to receive one Zoar Limited share for each Impact share held immediately prior to the merger’s effective time, as previously announced.
Impact Biomedical Inc. (IBO) approved a 1-for-12.62 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on September 23, 2026. The split is intended to support a proposed merger with Zoar Limited and efforts to regain compliance with NYSE American continued listing requirements, though it does not assure either outcome.
Every 12.62 issued and outstanding shares will be combined into one share, reducing the outstanding common shares from approximately 107,821,231 to approximately 8,543,679, with fractional shares rounded up to the nearest whole share. Proportional adjustments will be made to equity awards, related exercise prices, and shares reserved under equity plans, while authorized share capital remains unchanged, so ownership percentages are expected to stay the same apart from rounding. The company also corrected its previously announced merger exchange ratio, confirming Impact stockholders are expected to receive one Zoar Limited share for every one Impact share held immediately prior to the merger’s effective time, after giving effect to the reverse split.
Impact BioMedical, a Nevada-based biotechnology company, reported minimal operating revenue and continuing losses for the quarter ended June 30, 2026. Biotech retail sales from its Celios air purification products were $3,000 in the quarter and $10,000 for the first six months of 2026. The company recorded a Q2 net loss of $700,000 and a six-month net loss of $2,983,000, sharply lower than the prior-year periods when a large noncash fair value adjustment and interest on a related-party note drove losses.
Total assets were $16.7 million, dominated by $16.4 million of developed technology and other intangible assets, while cash was only $10,000. Current liabilities were $2.0 million, including $1.33 million due to majority owner DSS, with total stockholders equity of $14.0 million. Operating expenses for the first half rose to $3.0 million, driven by $1.44 million of stock-based compensation, although several cost categories declined. Management disclosed substantial doubt about the companys ability to continue as a going concern and reported that previously identified material weaknesses in internal control over financial reporting remain unresolved.
Impact BioMedical, Inc. reported very limited operating revenue and a larger loss for the quarter ended March 31, 2026. The company generated only $7,000 in biotech retail sales from its Celios air purification products, while total costs and expenses rose to $2,296,000.
Net loss was $2,284,000, compared with $1,278,000 a year earlier, driven mainly by a sharp increase in stock-based compensation to $1,440,000. Cash and cash equivalents were $20,000 at quarter end, and operations were funded partly by $482,000 of new related-party borrowings.
Total assets were $17,086,000, largely made up of $16,709,000 in intangible assets. Accumulated deficit widened to $51,794,000, and management disclosed that recurring losses and negative operating cash flows raise substantial doubt about the company’s ability to continue as a going concern. Material weaknesses in internal control over financial reporting remained unremediated.
West Park Capital, Inc. submitted a Form 144 notice concerning Common Stock. The excerpt shows 31,939,778 shares of Common Stock were issued to DSS on 06/21/2025 in full satisfaction of a Second Amended Promissory Note. The filing lists 107,821,231 (appears with date 04/22/2026) elsewhere in the header.
IMPACT BIOMEDICAL INC. Chief Financial Officer Todd D. Macko reported open-market sales of 45,000 shares of Common Stock. The transactions occurred on March 25 and March 27, 2026 at prices around $0.60 per share. After these sales, he directly holds 155,122 shares of Common Stock.